Market Cap: $196.77B
GI
Gilead Sciences, Inc.
GILD
NASDAQ (NASDAQ Global Select)USD
Market Cap: $196.77B
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…
Gilead Sciences (Ticker: GILD) achieves a significant regulatory milestone with the FDA's approval of Trodelvy as a first-line therapy for adult patients suffering from unresectable locally advanced o…
Gilead Sciences (Ticker: GILD) is currently making headlines after securing FDA approval for Trodelvy (sacituzumab govitecan-hziy), a significant development in the treatment of unresectable locally a…
Gilead Sciences has recently made a significant stride in HIV prevention with the acceptance of its supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) 300-mg tablets by the FDA. A New…
Gilead Sciences (Ticker: GILD) plays a pivotal role in the global health landscape, particularly highlighted by its recent donation of remdesivir to Uganda in response to the Ebola Bundibugyo virus di…
Gilead Sciences (Ticker: GILD) proactively addresses global health challenges through strategic initiatives, including a recent significant donation of remdesivir to Uganda amid an outbreak of the Ebo…
Gilead Sciences (Ticker: GILD) concludes a clinical trial partnership with Merck & Co. focusing on lung cancer treatments. The trial evaluates the effects of combining Trodelvy with Keytruda, aiming t…
Gilead Sciences has successfully completed the acquisition of Ouro Medicines, marking a significant step in its strategy to expand its portfolio in the autoimmune disease sector. This acquisition intr…
Gilead Sciences (Ticker: GILD) achieves major regulatory milestones that enhance its pharmaceutical portfolio, particularly within specialty diseases. A landmark moment arrives with the U.S. Food and…
Gilead Sciences (Ticker: GILD) is making significant strides in its operational strategy, focusing on expanding its therapeutic areas beyond HIV, which has been its cornerstone. At the recent Bank of…
Gilead Sciences (Ticker: GILD) is set to present new data on liver diseases at the upcoming European Association for the Study of the Liver (EASL) Congress. The company is particularly focusing on piv…
Gilead Sciences is actively enhancing its position in the biotechnology sector through important developments in its HIV and oncology drug pipelines. Recently, the U.S. Food and Drug Administration (F…
In a significant development, Gilead Sciences, a prominent biopharmaceutical company, is initiating a global health partnership to enhance access to lenacapavir, its twice-yearly injectable drug for H…
Gilead Sciences Positions Itself for Success in Autoimmune Therapies Gilead Sciences stands at the forefront of a transformative shift in the biotechnology landscape, emphasizing innovative approaches…
Gilead Sciences Expands Oncology Portfolio with Strategic Acquisition of Ouro Medicines Gilead Sciences announces a significant step in bolstering its oncology pipeline by acquiring Ouro Medicines for…
Oncolytics Biotech Forge Ahead with Innovative Cancer Treatments Oncolytics Biotech Inc. is making significant strides in the rapidly evolving oncology sector, which is on track to undergo a dramatic…
Eli Lilly Faces Pressure from Competitive Landscape in Obesity Drug Market The pharmaceutical sector is witnessing a seismic shift as competition intensifies within the obesity drug market, prompting…
Gilead Sciences: Navigating Diverse Analyst Perspectives Amid Market Evolution Recent analysis of Gilead Sciences by a cohort of 16 analysts reveals a complex landscape for the biopharmaceutical compa…
Gilead Sciences: Analyzing Diverse Market Sentiments Amidst Competitive Pressures Gilead Sciences, a prominent player in the biopharmaceutical industry, currently garners a spectrum of analyst opinion…
Oncolytics Biotech Leads Innovation in Colorectal Cancer Treatment Oncolytics Biotech Inc. is making significant strides in the oncology market with novel therapies aimed at treating complex forms of…
Transformative Advances in Oncology: Oncolytics Biotech and the Race for Better Colorectal Cancer Treatments Oncolytics Biotech Inc. stands at the forefront of a significant transformation in the onco…
Gilead Sciences Focuses on Advancing HIV Therapeutics Amidst Evolving Market Dynamics In the realm of healthcare and pharmaceuticals, Gilead Sciences remains at the forefront of developing innovative…
Gilead Sciences Seeks Enhanced Oncology Capabilities with Arcellx Acquisition Gilead Sciences Inc. makes headlines with its recent announcement of acquiring Arcellx Inc., a strategic move aimed at bol…
Analyst Split Casts Spotlight on Gilead's Pipeline Gilead Sciences is facing a pronounced divergence of opinion among sell‑side analysts, with 16 separate reports in the past three months reflecting a…
Investor Sentiment Spurs Strategic Focus at Gilead Sciences Gilead Sciences is responding to a measurable uptick in investor scrutiny by sharpening its focus on pipeline communication and regulatory m…